Eli Lilly blows past estimates, hikes sales outlook as Zepbound and Mounjaro demand surge again
Eli Lilly reported that sales of obesity drug Zepbound and diabetes treatment Mounjaro surged again in the third quarter.
We haven't written up this one. CNBC World has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
